Compare GSK Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AUROBINDO PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AUROBINDO PHARMA GSK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 52.1 14.3 365.0% View Chart
P/BV x 11.0 3.1 353.5% View Chart
Dividend Yield % 1.4 0.4 357.7%  

Financials

 GSK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
AUROBINDO PHARMA
Mar-18
GSK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,595809 444.4%   
Low Rs1,253504 248.6%   
Sales per share (Unadj.) Rs184.7281.1 65.7%  
Earnings per share (Unadj.) Rs26.341.4 63.6%  
Cash flow per share (Unadj.) Rs29.250.9 57.3%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.80.4 216.7%  
Book value per share (Unadj.) Rs126.3199.4 63.4%  
Shares outstanding (eoy) m169.40585.88 28.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.12.3 562.0%   
Avg P/E ratio x92.215.9 580.8%  
P/CF ratio (eoy) x83.112.9 644.2%  
Price / Book Value ratio x19.23.3 582.7%  
Dividend payout %76.16.0 1,258.3%   
Avg Mkt Cap Rs m410,626384,630 106.8%   
No. of employees `0005.017.3 28.6%   
Total wages/salary Rs m5,37221,308 25.2%   
Avg. sales/employee Rs Th6,306.79,500.7 66.4%   
Avg. wages/employee Rs Th1,083.11,229.4 88.1%   
Avg. net profit/employee Rs Th898.01,397.9 64.2%   
INCOME DATA
Net Sales Rs m31,281164,666 19.0%  
Other income Rs m1,0231,020 100.3%   
Total revenues Rs m32,304165,686 19.5%   
Gross profit Rs m6,00937,718 15.9%  
Depreciation Rs m4865,580 8.7%   
Interest Rs m6777 0.8%   
Profit before tax Rs m6,54032,380 20.2%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3738,183 29.0%   
Profit after tax Rs m4,45424,229 18.4%  
Gross profit margin %19.222.9 83.9%  
Effective tax rate %36.325.3 143.6%   
Net profit margin %14.214.7 96.8%  
BALANCE SHEET DATA
Current assets Rs m20,061121,878 16.5%   
Current liabilities Rs m14,54386,806 16.8%   
Net working cap to sales %17.621.3 82.8%  
Current ratio x1.41.4 98.2%  
Inventory Days Days57130 43.7%  
Debtors Days Days1468 20.6%  
Net fixed assets Rs m14,34381,037 17.7%   
Share capital Rs m1,694586 289.1%   
"Free" reserves Rs m19,704116,218 17.0%   
Net worth Rs m21,398116,804 18.3%   
Long term debt Rs m24,512 0.0%   
Total assets Rs m39,113211,052 18.5%  
Interest coverage x1,091.042.7 2,557.3%   
Debt to equity ratio x00 0.2%  
Sales to assets ratio x0.80.8 102.5%   
Return on assets %11.411.8 96.2%  
Return on equity %20.820.7 100.3%  
Return on capital %31.927.4 116.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53480,727 0.7%   
Fx outflow Rs m7,09134,700 20.4%   
Net fx Rs m-6,55746,027 -14.2%   
CASH FLOW
From Operations Rs m3,99419,548 20.4%  
From Investments Rs m-1,433-19,570 7.3%  
From Financial Activity Rs m-3,5848,642 -41.5%  
Net Cashflow Rs m-1,0238,922 -11.5%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.0 128.3%  
FIIs % 23.8 27.7 85.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   102,036 69,601 146.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS